1. Home
  2. NRIX vs QD Comparison

NRIX vs QD Comparison

Compare NRIX & QD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRIX
  • QD
  • Stock Information
  • Founded
  • NRIX 2009
  • QD 2014
  • Country
  • NRIX United States
  • QD China
  • Employees
  • NRIX N/A
  • QD N/A
  • Industry
  • NRIX Biotechnology: Pharmaceutical Preparations
  • QD Finance: Consumer Services
  • Sector
  • NRIX Health Care
  • QD Finance
  • Exchange
  • NRIX Nasdaq
  • QD Nasdaq
  • Market Cap
  • NRIX 728.6M
  • QD 761.2M
  • IPO Year
  • NRIX 2020
  • QD 2017
  • Fundamental
  • Price
  • NRIX $10.69
  • QD $4.70
  • Analyst Decision
  • NRIX Strong Buy
  • QD
  • Analyst Count
  • NRIX 14
  • QD 0
  • Target Price
  • NRIX $29.07
  • QD N/A
  • AVG Volume (30 Days)
  • NRIX 1.2M
  • QD 361.7K
  • Earning Date
  • NRIX 10-09-2025
  • QD 11-21-2025
  • Dividend Yield
  • NRIX N/A
  • QD N/A
  • EPS Growth
  • NRIX N/A
  • QD N/A
  • EPS
  • NRIX N/A
  • QD 0.42
  • Revenue
  • NRIX $88,381,000.00
  • QD $19,058,373.00
  • Revenue This Year
  • NRIX $74.59
  • QD N/A
  • Revenue Next Year
  • NRIX N/A
  • QD N/A
  • P/E Ratio
  • NRIX N/A
  • QD $10.92
  • Revenue Growth
  • NRIX 41.86
  • QD N/A
  • 52 Week Low
  • NRIX $8.18
  • QD $2.02
  • 52 Week High
  • NRIX $29.56
  • QD $5.08
  • Technical
  • Relative Strength Index (RSI)
  • NRIX 63.25
  • QD 60.47
  • Support Level
  • NRIX $8.20
  • QD $4.50
  • Resistance Level
  • NRIX $10.23
  • QD $4.77
  • Average True Range (ATR)
  • NRIX 0.50
  • QD 0.22
  • MACD
  • NRIX 0.27
  • QD 0.04
  • Stochastic Oscillator
  • NRIX 99.80
  • QD 92.78

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About QD Qudian Inc. each representing one

Qudian Inc is a consumer-oriented technology company engaged in the operation of online platforms to provide small consumer credit products in the People's Republic of China. It aims to empower financial institutions with its technological capabilities, help them improve marketing and operating efficiency, and enable financial institutions to efficiently connect their diversified financial products with scene traffic across the entire network It derives a majority of its revenue from the People's Republic of China.

Share on Social Networks: